OakChart

Definium Therapeutics Inc

DFTXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 11:25 AM ET

34.71+0.07 (0.20%)
2026-11-11 17:26 CET
Market cap
4,654.47 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-337.48 USD m
Free cash flow, TTM
-188.74 USD m
EPS diluted, TTM
-3.03
P/E
-
Compare

Price

DFTX against its 20, 50 and 200-day averages
2050200beatmiss
20.0030.0040.0050.0010.1M20.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DFTXclose 34.7120-day 34.6850-day 36.31200-day 30.2734.7152w high

30.2% under the 52-week high of 49.70 on 7 Aug 2026. 52-week low 10.47 on 21 Nov 2025. Last 15 sessions, 29.7% high to low

Profile

DFTX
52-week range, 62% of the way up
10.4649.70

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

IndexRUT
Employees106
IPONov 15, 2016
Beta2.22
ATR, 14d2.11
Rel volume0.47
Short float7.57%
Insider own5.49%
Inst own85.19%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.75B
Enterprise Value3.74B
Income-337.48M
Sales0.00M
Book/sh7.07
Cash/sh7.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees106
IPONov 15, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.91
P/C4.54
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio15.53
Current Ratio15.53
Debt/Eq0.04
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.03
EPS next Y-1.99
EPS next Q-0.51
EPS this Y-46.60%
EPS next Y33.96%
EPS next 5Y25.46%
EPS past 3/5Y-3.78% -1.48%
Sales past 3/5Y- -
EPS Y/Y TTM-53.65%
Sales Y/Y TTM-
EPS Q/Q52.13%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.34.27% -

Ownership

Insider Own5.49%
Insider Trans-1.86%
Inst Own85.19%
Inst Trans34.96%
ROA-51.48%
ROE-61.44%
ROIC-33.59%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.07%
SMA50-4.41%
SMA20014.65%
Trades-

Technical

Shs Outstand136.89M
Shs Float126.99M
Short Float7.57%
Short Ratio4.51
Short Interest9.61M
52W High49.70 -30.16%
52W Low10.46 231.69%
Volatility6.97% 5.72%
ATR (14)2.11
RSI (14)48.60
Beta2.22
Rel Volume0.47
Avg Volume2.13M
Volume331,098

Performance

Perf Week6.15%
Perf Month0.96%
Perf Quarter-20.93%
Perf Half Y57.70%
Perf YTD159.22%
Perf Year178.12%
Perf 3Y1288.40%
Perf 5Y2.84%
Perf 10Y-
Recom1.05
Target Price72.78
Prev Close34.64
Price34.71
Change %0.20%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedJJP MorganOverweight$84+142.0%
Aug 18, 2026InitiatedBBofA SecuritiesBuy$75+116.1%
Jul 27, 2026InitiatedWWells FargoOverweight$68+95.9%
Jun 23, 2026ReiteratedNNeedhamBuy$38 → $50+44.1%
Apr 17, 2026InitiatedSStifelBuy$30-13.6%
Apr 10, 2026InitiatedPPiper SandlerOverweight$49+41.2%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$25-28.0%
Jan 30, 2026InitiatedJJefferiesBuy$30-13.6%
Oct 13, 2025InitiatedNNeedhamBuy$28-19.3%
Aug 04, 2025ResumedOOppenheimerOutperform$25-28.0%

Peers

Mkt cap
TickerCompanyMkt cap
GHRSGH Research PLC1.34B
HELPHelus Pharma Inc714.53M
CMPSCompass Pathways Plc ADR1.32B
AXSMAxsome Therapeutics Inc7.80B
ANROAlto Neuroscience Inc1.18B
SPTXSeaport Therapeutics Inc1.13B
ACADAcadia Pharmaceuticals Inc3.16B
DRUGBright Minds Biosciences Inc218.49M
LBRXLB Pharmaceuticals Inc1.45B
NBIXNeurocrine Biosciences Inc17.40B

Insider trading

latest 14 of 36
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Karlin DanielChief Medical OfficerSep 25 '26Sale36.5710,853396,894792,846Sep 29 09:15 PM
Barrow RobertChief Executive OfficerSep 25 '26Sale36.5731,5501,153,7842,213,090Sep 29 09:14 PM
Wiley Matthew T.Chief Commercial OfficerSep 25 '26Sale36.573,097113,257359,036Sep 29 09:12 PM
Sullivan MarkChief Legal OfficerSep 25 '26Sale36.5714,051513,845494,228Sep 29 09:10 PM
Roberts BrandiChief Financial OfficerSep 25 '26Sale36.573,377123,497394,528Sep 29 09:08 PM
MARK SULLIVANOfficerSep 25 '26Proposed Sale36.7314,051516,093Sep 25 04:19 PM
BRANDI ROBERTSOfficerSep 25 '26Proposed Sale36.733,377124,037Sep 25 04:15 PM
MATTHEW THOMAS WILEYOfficerSep 25 '26Proposed Sale36.733,097113,753Sep 25 04:14 PM
DANIEL ROLLINGS KARLINOfficerSep 25 '26Proposed Sale36.7310,853398,631Sep 25 04:08 PM
ROBERT B BARROWOfficerSep 25 '26Proposed Sale36.7331,5501,158,832Sep 25 04:06 PM
Vallone Carol ADirectorSep 18 '26Option Exercise35.521,08638,57522,296Sep 18 09:55 PM
Krebs AndreasDirectorSep 18 '26Option Exercise35.521,62957,86221,402Sep 18 09:55 PM
Barrow RobertChief Executive OfficerSep 03 '26Sale37.9419,023721,7331,494,640Sep 04 09:30 PM
ROBERT B BARROWOfficerSep 03 '26Proposed Sale37.7519,023718,145Sep 03 04:28 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
VHTVanguard Health Care ETFAUM: 21.51B
CGMMCapital Group U.S. Small and Mid Cap ETFAUM: 3.67B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M

News

latest 14 of 206
  • Definium Beats On A Warrant-Aided Loss As Two More Phase 3 Wins De-Risk DT120, But The Stock Still Sits Near Its Quarter Lows (Earnings Whispers) +6.37%
  • Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights (Business Wire)
  • Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress (Business Wire)
  • Definium Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
  • Definium's Q3 Report Must Show GAD Data Answers And Commercial Discipline After 21% Slide (Earnings Whispers) -10.62%
  • Loading…
  • Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026 (Business Wire)
  • Jefferies Highlights Three Biotech Stocks With Blockbuster Potential (Investing.com)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits) -8.52%
  • Definium tees up regulatory submission for psychedelic on Phase III hat trick (Pharmaceutical Technology)
  • DFTX Stock Climbs As High As 12% On Unprecedented Anxiety Data For LSD-Based Drug (Stocktwits)
  • First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip. (Barrons.com)
  • Definium Therapeutics Shares Rise 20% After Phase 3 Anxiety Trial Meets Primary Endpoint (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.370-0.563-0.3700.000.0017
2026Q22026-08-06-1.440-0.541-1.4360.000.0015
2026Q12026-05-07-0.710-0.492-0.7090.000.0014
2025Q42026-02-26-0.510-0.484-0.5110.000.0014
2025Q32025-11-06-0.780-0.501-0.7830.000.0011
2025Q22025-07-31-0.500-0.380-0.5010.000.009
2025Q12025-05-08-0.270-0.363-0.2750.000.0010
2024Q42025-03-06-0.410-0.293-0.4140.000.0010
2024Q32024-11-07-0.180-0.277-0.2750.000.0010
2024Q22024-08-13-0.080-0.327-0.0810.000.0010
2024Q12024-05-08-1.140-0.529-1.1370.000.007
2023Q42024-02-28-0.580-0.463-0.5920.000.007
2023Q32023-11-02-0.450-0.654-0.4510.000.007
2023Q22023-08-03-0.760-0.534-0.7550.000.008
2023Q12023-05-04-0.650-0.422-0.6520.000.006
2022Q42023-03-09-0.130-0.492-0.1290.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.500-1.500-1.9120.000.00
2021FY-3.450-3.500-3.3980.000.00
2022FY-1.840-2.296-1.8410.000.00
2023FY-2.440-2.274-2.4450.000.00
2024FY-1.540-1.432-1.5420.000.00
2025FY-2.060-2.003-2.0600.001.50
2026FY--3.020--0.00
2027FY--1.994--29.35
2028FY--0.853--267.02
2029FY-1.100--645.16
2030FY-3.825--1,168

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1012000.000.000.00
2026Q4S2026-11-0912000.000.000.00
2026Q4S2026-10-0812000.000.000.00
2026Q4S2026-09-1011000.000.000.00
2026Q4S2026-08-1710000.000.000.00
2026Q4S2026-08-079000.000.000.00
2026Q4S2026-07-249000.000.000.00
2026Q4S2026-05-318000.000.000.00
2026Q4S2026-05-089000.000.000.00
2026Q4S2026-04-219000.000.000.00
2026Q4S2026-04-088000.000.000.00
2026Q4S2026-02-277000.000.000.00
2026Q4S2026-02-205000.000.000.00
2026Q4S2026-01-304000.000.000.00

Estimate history

EPS, annual-1.809-4.853-2.746-1.912-3.398-1.841-2.445-1.542-2.058-3.0306
Period201620172018202020212022202320242025TTM
EPS, quarterly-0.275-0.414-0.275-0.501-0.783-0.511-0.709-1.436-0.375
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201620172018202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.080.3080.3524.07628.12637.97941.10175.10198.776136.888
Period201620172018202020212022202320242025MRQ
Shares, quarterly81.5975.10175.51175.80376.77498.776104.045134.366136.888
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2018FY
Total Revenue0.000.000.000.000.000.000.00-0.00
Cost of Goods Sold Incl. D&A0.000.000.533.163.222.620.00-0.01
Gross Profit0.000.00-0.53-3.16-3.22-2.620.00--0.01
Selling, General and Administrative Excl. Other254.15166.31103.3990.7063.1190.9433.03-0.86
Research and Development169.81117.6764.7748.9632.9932.1718.63--
Other Operating Expense0.000.000.000.000.000.000.00-0.00
Operating Income-254.15-166.31-103.92-93.87-66.33-93.55-33.03--0.86
Interest Expense4.905.482.28-0.000.360.16-0.00
Unusual Expense98.9822.8313.406.64-7.840.300.87--
Net Income Before Taxes-337.48-183.79-108.68-95.73-56.80-94.19-33.94--0.86
Income Taxes0.000.000.000.000.00-1.160.00-0.00
Consolidated Net Income-337.48-183.79-108.68-95.73-56.80-93.04-33.94--0.86
Net Income From Continuing Operations-337.48-183.79-108.68-95.73-56.80-93.04-33.94--0.86
Net Income-337.48-183.79-108.68-95.73-56.80-93.04-33.94--0.86
EPS (Recurring)-1.97-1.88-1.41-2.33-2.02-3.39-1.88--2.75
EPS (Basic, Before Extraordinaries)-3.03-2.06-1.54-2.44-1.84-3.40-1.91--2.75
EPS (Diluted)-3.03-2.06-1.54-2.44-1.84-3.40-1.91--2.75
EBITDA-254.15-166.31-103.39-90.70-63.11-90.94-33.03--0.86
Non-Operating Income (Expense)20.5510.8310.924.771.690.020.13-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.00-0.00
Stock Option Compensation Expense33.1520.1016.9115.4913.7131.187.41-0.15
Shares Outstanding136.8998.7875.1041.1037.9828.1324.08-0.35
Market Capitalization4,654.474,654.47217.98292.24292.24582.222,202.92-4.21

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other72.2875.0859.2247.5845.6740.9032.1632.46
Research and Development46.1448.6741.4833.5230.9829.8123.3621.76
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-72.28-75.08-59.22-47.58-45.67-40.90-32.16-32.46
Interest Expense1.151.231.251.271.272.340.600.66
Unusual Expense-12.3586.2320.055.0622.552.23-7.004.85
Net Income Before Taxes-50.96-158.99-77.10-50.44-67.27-42.74-23.35-34.74
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-50.96-158.99-77.10-50.44-67.27-42.74-23.35-34.74
Net Income From Continuing Operations-50.96-158.99-77.10-50.44-67.27-42.74-23.35-34.74
Net Income-50.96-158.99-77.10-50.44-67.27-42.74-23.35-34.74
EPS (Recurring)-0.44-0.89-0.58-0.47-0.60-0.48-0.33-0.37
EPS (Basic, Before Extraordinaries)-0.37-1.44-0.71-0.51-0.78-0.50-0.27-0.41
EPS (Diluted)-0.37-1.44-0.71-0.51-0.78-0.50-0.27-0.41
EBITDA-72.28-75.08-59.22-47.58-45.67-40.90-32.16-32.46
Non-Operating Income (Expense)10.123.563.413.472.222.732.413.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.789.647.135.605.825.253.433.45
Shares Outstanding136.89134.37104.0498.7876.7775.8075.5175.10
Market Capitalization4,654.475,130.511,884.291,011.66890.77490.34217.98217.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY
Cash & Short Term Investments411.59273.7499.70142.14133.5480.09-0.151.69
Short Term Receivables0.000.000.000.000.000.00-0.010.01
Inventories0.000.000.000.000.000.00-0.000.00
Other Current Assets7.737.884.173.913.681.43-0.040.07
Total Current Assets419.32281.62103.87146.06137.2281.52-0.201.77
Net Property, Plant & Equipment0.000.000.000.000.000.00-0.060.07
Total Investments and Advances0.000.000.000.000.000.00-0.140.07
Intangible Assets19.9219.9220.4523.6126.790.00-0.000.00
Other Assets0.860.610.220.330.000.00-3.132.12
Total Assets440.10302.15124.54169.99164.0081.52-3.534.03
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.070.000.00-0.000.02
Accounts Payable5.352.010.000.000.000.00-0.000.00
Other Current Liabilities61.3536.8432.2517.8210.413.01-0.010.06
Total Current Liabilities66.7038.8532.2517.8910.413.01-0.010.08
Long Term Debt40.5821.8514.130.000.000.00-0.000.00
Provision for Risks Charges0.000.000.000.000.000.00-0.000.00
Other Liabilities0.500.000.031.181.932.64-0.000.00
Total Liabilities107.7760.7046.4119.0812.345.65-0.010.08
Non-Equity Reserves0.000.000.000.000.000.00-0.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00-0.000.00
Common Equity332.33241.4578.13150.92151.6675.87-3.523.95
Total Shareholders Equity332.33241.4578.13150.92151.6675.87-3.523.95
Accumulated Minority Interest0.000.000.000.000.000.00-0.000.00
Total Equity332.33241.4578.13150.92151.6675.87-3.523.95
Total Liabilities & Stockholders Equity440.10302.15124.54169.99164.0081.52-3.534.03
Book Value Per Share3.363.211.903.975.393.15-10.0812.82
Tangible Book Value Per Share3.162.951.403.354.443.15-10.0812.82
Full-Time Employees1067457484150---
Price to Book Ratio4.902.812.352.353.8426.46-1.203.92
Return on Assets-49.52-50.94-65.01-34.01-74.53-80.37--22.70-58.00
Return on Equity-64.06-68.01-83.59-37.54-79.20-86.35--24.18-60.22
Return on Invested Capital-49.29-41.28-103.76-37.63-61.34-44.73--24.34-31.08
Quick Ratio6.297.253.228.1613.1827.10-24.1422.02
Current Ratio6.297.253.228.1613.1827.10-24.1422.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2018FY
Net Income-332.83-183.79-108.68-95.73-56.80-93.04-33.94--0.86
Depreciation-0.000.533.163.222.620.00-0.01
Other Funds (Non Cash)134.0842.8032.3721.927.2242.728.28-0.15
Funds from Operations-198.75-141.00-75.79-70.65-46.36-47.70-25.66--0.70
Extraordinary Item0.000.000.000.000.000.000.00-0.00
Changes in Working Capital10.029.44-3.346.28-3.781.882.06--0.02
Income Taxes Payable------1.160.00--
Cash from Operating Activities-188.74-131.56-79.13-64.37-50.14-45.82-23.60--0.72
Capital Expenditures0.000.000.000.000.000.000.00--1.04
Net Assets From Acquisitions0.000.000.000.000.00-0.300.00--
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00--
Purchase or Sale of Investments-603.26-151.610.000.000.000.000.00-1.59
Purchase of Investments-792.77-268.360.000.000.000.000.00--0.07
Sale Or Maturity of Investments189.51116.750.000.000.000.000.00-1.66
Other Uses0.000.000.000.000.000.000.00-0.00
Other Sources0.000.000.000.000.000.000.00-0.00
Cash from Investing Activities-603.26-151.610.000.000.00-0.300.00-0.54
Cash Dividends Paid0.000.000.000.000.000.000.00-0.00
Change in Capital Stock1,017.49247.72243.387.6959.4698.8296.70-0.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.00
Sale of Common Pref Stock1,017.49247.72243.387.6959.4698.8296.70-0.33
Proceedsfrom Stock Options993.97243.32234.397.5358.5481.9271.60-0.33
Issuance or Reduction of Debt, Net-0.2619.559.8714.160.000.000.00--0.02
Change in Long Term Debt-0.2619.559.8714.160.000.000.00-0.00
Issuance of Long Term Debt-0.5541.559.8714.160.000.000.00-0.00
Reduction of Long Term Debt0.29-22.000.000.000.000.000.00-0.00
Net Financing Active Other Cash Flow0.000.00-0.050.00-0.410.000.00-0.00
Other Financing Activities Uses0.000.00-0.050.00-0.410.000.00-0.00
Cash from Financing Activities1,017.23267.27253.2021.8559.0598.8296.70-0.31
Exchange Rate Effect-0.00-0.01-0.030.08-0.310.740.28-0.02
Net Change in Cash225.23-15.90174.04-42.448.6053.4573.39-0.15
Free Cash Flow-188.74-131.56-79.13-64.36-50.14-45.82-23.60--0.72
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,046.851,083.88373.42411.59209.07182.99
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.918.227.147.736.786.14
Total Current Assets1,051.761,092.10380.56419.32215.85189.14
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.0054.86
Intangible Assets19.9219.9219.9219.9219.9219.92
Other Assets2.610.880.810.861.151.17
Total Assets1,074.281,112.90401.29440.10236.92265.09
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable9.286.967.135.358.114.22
Other Current Liabilities58.45150.2473.9861.3557.3033.74
Total Current Liabilities67.73157.2081.1166.7065.4237.96
Long Term Debt36.6636.4740.7740.5840.3841.19
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.860.550.560.500.520.54
Total Liabilities106.25194.22122.44107.77106.3279.69
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity968.03918.68278.85332.33130.60185.40
Total Shareholders Equity968.03918.68278.85332.33130.60185.40
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity968.03918.68278.85332.33130.60185.40
Total Liabilities & Stockholders Equity1,074.281,112.90401.29440.10236.92265.09
Book Value Per Share7.076.842.683.361.702.45
Tangible Book Value Per Share6.936.692.493.161.442.18
Full-Time Employees---106--
Price to Book Ratio4.9017.555.627.874.822.20
Return on Assets-51.48-51.35-70.22-49.52-60.39-42.95
Return on Equity-61.44-64.09-94.70-64.06-85.59-59.11
Return on Invested Capital-5.07-16.65-24.12-13.53-39.34-18.86
Quick Ratio15.536.954.696.293.304.98
Current Ratio15.536.954.696.293.304.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-49.07-157.89-77.10-48.77-68.15-43.91
Depreciation---0.000.000.00
Other Funds (Non Cash)-5.6399.3229.0211.3630.055.08
Funds from Operations-54.70-58.56-48.08-37.41-38.09-38.83
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.826.235.45-4.488.218.19
Cash from Operating Activities-51.88-52.33-42.63-41.89-29.89-30.64
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-367.33-315.4642.0037.5316.10-43.10
Purchase of Investments-436.14-354.080.00-2.55-26.47-77.44
Sale Or Maturity of Investments68.8138.6242.0040.0842.5734.34
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-367.33-315.4642.0037.5316.10-43.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.12758.705.31246.360.760.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.12758.705.31246.360.760.12
Proceedsfrom Stock Options-3.76751.224.11242.400.660.01
Issuance or Reduction of Debt, Net0.000.000.00-0.26-0.0419.90
Change in Long Term Debt0.000.000.00-0.26-0.0419.90
Issuance of Long Term Debt0.000.000.00-0.55-0.0942.29
Reduction of Long Term Debt0.000.000.000.290.05-22.39
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities7.12758.705.31246.100.7120.01
Exchange Rate Effect-0.00-0.000.000.00-0.020.03
Net Change in Cash-412.10390.904.68241.74-13.09-53.70
Free Cash Flow-51.88-52.33-42.63-41.89-29.89-30.64

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.57%9.6M127.0M2.15M
2026-10-157.91%10.0M127.0M2.14M
2026-09-308.94%11.3M126.9M2.17M
2026-09-159.29%11.8M126.8M2.96M
2026-08-317.67%9.8M128.2M2.96M
2026-08-147.00%9.0M128.2M2.98M
2026-07-318.34%10.7M128.9M2.77M
2026-07-158.44%10.6M126.1M2.92M
2026-06-3011.51%14.5M126.1M2.81M
2026-06-1510.27%10.6M103.6M1.91M
2026-05-298.99%9.4M104.9M1.82M
2026-05-158.87%9.2M104.3M1.74M
2026-04-308.90%9.4M105.1M1.75M
2026-04-1510.22%9.8M96.1M1.73M
2026-03-3116.03%15.1M94.4M1.82M
2026-03-1315.91%15.0M94.4M1.91M
2026-02-2720.50%19.3M94.4M1.86M
2026-02-1320.93%19.5M93.2M1.88M
2026-01-3018.62%17.7M94.9M2.04M
2026-01-1522.92%16.8M73.4M2.01M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call24.008.6012.500.003.1660.000.000.948-0.0520.006
call25.007.7011.507.462.9351.000.000.944-0.0500.006
call26.006.8010.500.002.7110.000.000.938-0.0490.007
call27.006.609.500.002.5380.000.000.857-0.1160.012
call28.005.208.407.002.2830.000.000.844-0.1110.013
call29.004.108.008.602.3094.000.000.829-0.1070.014
call30.003.207.005.502.10880.000.000.808-0.1000.015
call31.002.256.502.552.1542.000.000.777-0.0970.016
call32.002.105.400.001.9030.000.000.668-0.1790.020
call33.001.604.003.601.4543110.000.626-0.1930.021
call34.001.703.202.201.3101270.000.583-0.1840.021
call35.001.351.751.500.8602,8712.000.520-0.1410.022
call36.000.851.501.300.9433121.000.442-0.1240.022
call37.000.601.701.751.1071,6892.000.392-0.1320.021
call38.000.400.950.750.9761462.000.305-0.1050.019
call39.000.252.050.601.10381.000.000.279-0.1130.018
call40.000.301.050.451.2214150.000.260-0.1200.018
call41.000.051.950.601.34239.000.000.243-0.1270.017
call42.000.051.200.201.4315180.000.232-0.1330.017
call43.000.050.500.181.2441070.000.154-0.0890.013
call44.000.000.650.351.30922.000.000.148-0.0920.013
call45.000.000.950.251.4192130.000.140-0.0950.012
call46.000.051.700.101.47438.000.000.136-0.0970.012
call47.000.001.650.001.5450.000.000.131-0.1000.012
call50.000.000.400.061.6721870.000.103-0.0900.010
put24.000.000.700.002.1410.000.00-0.108-0.1180.010
put25.000.000.750.311.9211010.00-0.120-0.1130.011
put26.000.000.200.101.7881210.00-0.136-0.1150.012
put27.000.000.900.351.6082580.00-0.149-0.1100.012
put28.000.000.950.431.5111310.00-0.156-0.1080.013
put29.000.002.950.301.33438.000.00-0.174-0.1020.014
put30.000.000.750.381.1774,0781.00-0.193-0.0960.015
put31.000.250.801.051.05840.000.00-0.222-0.0940.016
put32.000.052.151.001.60133.000.00-0.327-0.1760.020
put33.000.652.901.401.7181080.00-0.379-0.1880.021
put34.000.953.301.681.7011540.00-0.417-0.1800.021
put35.001.204.902.271.4892210.00-0.483-0.1360.022
put36.002.003.406.351.22930.000.00-0.556-0.1200.022
put37.002.254.107.101.22559.000.00-0.611-0.1280.021
put38.002.054.907.701.31123.000.00-0.694-0.1010.019
put39.003.106.907.581.8884.000.00-0.724-0.1090.018
put40.004.107.604.951.91428.000.00-0.740-0.1160.018
put41.005.508.700.002.1010.000.00-0.755-0.1220.017
put42.005.809.308.171.9795.000.00-0.769-0.1290.017
put43.006.5010.508.602.1750.000.00-0.846-0.0850.013
put44.007.5011.509.802.3412.000.00-0.852-0.0870.013
put45.008.5012.500.002.0750.000.00-0.862-0.0910.012
put46.009.5012.600.001.9900.000.00-0.865-0.0920.012
put47.0010.5014.100.002.2430.000.00-0.871-0.0950.011
put50.0013.5017.500.002.8970.000.00-0.897-0.0850.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-05SCHEDULE 13GSEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09003.02M6
2026-080000
2026-070000
2026-06002.62M5
2026-050000
2026-040000
2026-0300797.00K3
2026-020000
2026-010000
2025-1200560.94K3
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.10.30%
FMR LLC6.76%
Avoro Capital Advisors LLC6.59%
DRIEHAUS CAPITAL MANAGEMENT LLC6.28%
Jupiter Topco LLC5.15%
Capital World Investors4.92%
PRICE T ROWE ASSOCIATES INC /MD/4.27%
STATE STREET CORP2.81%
Capital International Investors2.72%
GEODE CAPITAL MANAGEMENT, LLC2.71%

Funds

Fund% owned
SMALLCAP World Fund Inc7.05%
iShares Russell 2000 ETF3.07%
Multi-Manager Directional Alternative Strategies Fund1.58%
VANGUARD EXTENDED MARKET INDEX FUND1.36%
T. Rowe Price Health Sciences Fund, Inc.1.18%
iShares Russell 2000 Growth ETF1.09%
Fidelity Small Cap Index Fund1.07%
T. Rowe Price New Horizons Fund, Inc.1.05%
iShares Biotechnology ETF0.68%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.67%

OakChart. DFTX. Cached 15 minutes.